12 result(s) for Phase I Clinical Trials
PI Name | Protocol # | Title |
---|---|---|
Christopher Ryan | STUDY00020946 | A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor |
Shivaani Kummar | STUDY00021194 | A phase 1 study of SGN-CD228A in select advanced solid tumors |
Shivaani Kummar | STUDY00021766 | A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination with Avelumab in Patients with Advanced Solid Tumors Who Have Progressed during or after Treatment with Anti-PD-(L)1 therapy |
Shivaani Kummar | STUDY00021819 | A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors |
Shivaani Kummar | STUDY00022082 | A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors |
Shivaani Kummar | STUDY00022223 | A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors |
Shivaani Kummar | STUDY00022760 | A Phase 2, Multi-Arm Study of Magrolimab in Patients with Solid Tumors |
Shivaani Kummar | STUDY00022863 | A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors |
Shivaani Kummar | STUDY00022902 | Master Protocol: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations |
Shivaani Kummar | STUDY00023157 | A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies |
Shivaani Kummar | STUDY00023236 | A Phase 1 Study of SGN-STNV in Advanced Solid Tumors |
Eric Roeland | STUDY00023857 | A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients |